Efsubaglutide Alfa Injection

DRUG3 trials

Sponsors

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd., The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Conditions

Diabete Type 2Metabolic SurgeryObesityType2 DiabetesWeight Loss

Phase 1

A Bridging Study of Efsubaglutide Alfa in Healthy Adults in Brazil

Not yet recruitingNCT07518121

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.Diabete Type 2

Start: 2026-06-01End: 2026-10-31Target: 48Updated: 2026-04-08

Phase 2

A Study of 3mg Once Every Two Weeks Administration of Efsubaglutide Alfa Injection in Type 2 Diabetes Patients.

CompletedNCT06849843

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.Type2 Diabetes

Start: 2024-12-18End: 2025-05-29Updated: 2025-09-12

Phase 4

Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery

RecruitingNCT07163650

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolMetabolic Surgery, Obesity, Weight Loss

Start: 2025-09-16End: 2027-02-28Target: 60Updated: 2026-01-27